Harrow has launched BYOOVIZ® (ranibizumab-nuna) in the United States. The product is the first FDA-approved biosimilar to Genentech’s Lucentis®.
Samsung Bioepis developed the drug, which Harrow is relaunching after securing exclusive U.S. commercialization rights. Biogen originally introduced the product to the market in 2022 before the rights were transferred.
BYOOVIZ® is approved for several retinal diseases, including neovascular (wet) age-related macular degeneration (AMD). It represents the first interchangeable biosimilar for ophthalmology in the U.S.
The launch positions Harrow within the estimated $9 billion anti-VEGF market. This move provides a clinically proven and more affordable treatment option for sight-threatening conditions.